Meta-Analysis on the Therapeutic Effect of Transcatheter Arterial Chemoembolization Combined with Portal Vein Embolization.

IF 2 4区医学 Q3 ONCOLOGY

Chemotherapy Pub Date : 2024-01-01 Epub Date: 2024-05-28 DOI:10.1159/000539347

Xin-Jie Liu, Ping-Wei Song, Li-Gang Wang, Hai-Ning Zou, Lin-Lin Zhang

{"title":"Meta-Analysis on the Therapeutic Effect of Transcatheter Arterial Chemoembolization Combined with Portal Vein Embolization.","authors":"Xin-Jie Liu, Ping-Wei Song, Li-Gang Wang, Hai-Ning Zou, Lin-Lin Zhang","doi":"10.1159/000539347","DOIUrl":null,"url":null,"abstract":"Introduction: The aim of the study was to conduct a systematic review to explore the therapeutic effect of transcatheter arterial chemoembolization (TACE) combined with portal vein embolization (PVE) for patients with hepatocellular carcinoma (HCC).Methods: Chinese and English databases (PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang database, and VIP database) were searched from database inception to August 15, 2023. Studies comparing TACE combined with PVE versus TACE alone for patients with HCC were included. The degree of heterogeneity was assessed using I2 statistics and a Q test. The effect size was represented by risk ratio and mean difference (MD), and the effect size range was estimated using a 95% confidence interval (CI).Results: Eight eligible studies were included in the systematic review, involving 689 participants. The results showed that the future liver residual (FLR) of patients treated with TACE combined with PVE was significantly higher than that of those treated with PVE alone (MD = 3.99%; 95% CI: 1.03-6.94). Furthermore, compared with PVE alone, TACE combined with PVE had a positive effect on disease-free survival (odds ratio [OR] = 2.16; 95% CI: 1.20-3.88), recurrence rate (OR = 0.79; 95% CI: 0.07-9.42), and complications (OR = 0.53; 95% CI: 0.30-0.96). There was no statistically significant impact on mortality with TACE combined with PVE treatment.Conclusion: The combination of TACE with PVE can significantly reduce the FLR of patients with HCC, with higher disease-free survival, lower recurrence rate, and fewer complications.","PeriodicalId":10047,"journal":{"name":"Chemotherapy","volume":" ","pages":"212-223"},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000539347","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The aim of the study was to conduct a systematic review to explore the therapeutic effect of transcatheter arterial chemoembolization (TACE) combined with portal vein embolization (PVE) for patients with hepatocellular carcinoma (HCC).

Methods: Chinese and English databases (PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang database, and VIP database) were searched from database inception to August 15, 2023. Studies comparing TACE combined with PVE versus TACE alone for patients with HCC were included. The degree of heterogeneity was assessed using I2 statistics and a Q test. The effect size was represented by risk ratio and mean difference (MD), and the effect size range was estimated using a 95% confidence interval (CI).

Results: Eight eligible studies were included in the systematic review, involving 689 participants. The results showed that the future liver residual (FLR) of patients treated with TACE combined with PVE was significantly higher than that of those treated with PVE alone (MD = 3.99%; 95% CI: 1.03-6.94). Furthermore, compared with PVE alone, TACE combined with PVE had a positive effect on disease-free survival (odds ratio [OR] = 2.16; 95% CI: 1.20-3.88), recurrence rate (OR = 0.79; 95% CI: 0.07-9.42), and complications (OR = 0.53; 95% CI: 0.30-0.96). There was no statistically significant impact on mortality with TACE combined with PVE treatment.

Conclusion: The combination of TACE with PVE can significantly reduce the FLR of patients with HCC, with higher disease-free survival, lower recurrence rate, and fewer complications.

查看原文本刊更多论文

经导管动脉化疗栓塞联合门静脉栓塞治疗效果的 Meta 分析。

目的对经导管动脉化疗栓塞术（TACE）联合门静脉栓塞术（PVE）治疗肝细胞癌（HCC）患者的疗效进行系统综述：方法：检索从数据库开始到2023年8月15日的中英文数据库（PubMed、Web of Science、Cochrane Library、中国国家知识基础设施、万方数据库和VIP数据库）。纳入了对 HCC 患者进行 TACE 联合 PVE 与单纯 TACE 比较的研究。使用 I2 统计量和 Q 检验评估异质性程度。效应大小用风险比（RR）和平均差（MD）表示，效应大小范围用95%置信区间（CI）估算：系统综述共纳入了 8 项符合条件的研究，涉及 689 名参与者。结果显示，接受TACE联合PVE治疗的患者的未来肝脏残留率（FLR）明显高于接受单纯PVE治疗的患者（MD=3.99%；95%CI：1.03-6.94）。此外，与单纯 PVE 相比，TACE 联合 PVE 对无病生存率（几率比 [OR]=2.16; 95%CI: 1.20-3.88）、复发率（OR=0.79; 95%CI: 0.07-9.42）和并发症（OR=0.53; 95%CI: 0.30-0.96）有积极影响。TACE联合PVE治疗对死亡率没有统计学意义：结论：TACE与PVE联合治疗可显著降低HCC患者的FLR，无病生存率更高，复发率更低，并发症更少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chemotherapy 医学-药学

CiteScore

5.80

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal publishes original research articles and state-of-the-art reviews on all aspects of antimicrobial and antitumor chemotherapy. The results of experimental and clinical investigations into the microbiological and pharmacologic properties of antibacterial, antiviral and antitumor compounds are major topics of publication. Papers selected for the journal offer data concerning the efficacy, toxicology, and interactions of new drugs in single or combined applications. Studies designed to determine the pharmacokinetic and pharmacodynamics properties of similar preparations and comparing their efficacy are also included. Special emphasis is given to the development of drug-resistance, an increasing problem worldwide.